Inceptionr LLC Sells 2,279 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Inceptionr LLC lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 11.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 17,329 shares of the biopharmaceutical company’s stock after selling 2,279 shares during the period. Inceptionr LLC’s holdings in Catalyst Pharmaceuticals were worth $362,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $27,000. Larson Financial Group LLC raised its stake in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $65,000. KBC Group NV raised its stake in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $134,000. Institutional investors own 79.22% of the company’s stock.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 157,879 shares of company stock worth $3,535,595. 11.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several recent analyst reports. Bank of America reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Finally, Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $32.50.

Catalyst Pharmaceuticals Trading Up 1.3 %

NASDAQ:CPRX opened at $21.96 on Friday. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of 18.61, a PEG ratio of 3.31 and a beta of 0.84. The firm has a fifty day simple moving average of $22.28 and a two-hundred day simple moving average of $21.51. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $24.64.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.